This study shows that the administration of nortriptyline induces a pattern of c-Fos expression in the central nervous system of rats that resembles the typical, inverted U-shaped dose-response curve observed in clinical pharmacokinetic studies in humans. This did not occur following the use of desipramine, an alternative noradrenergic antidepressant drug whose clinical efficacy is not associated with this type of dose-response relationship.
Previous studies have suggested that there is an optimum range of nortriptyline blood levels, a therapeutic window above or below which depressed patients respond poorly or do not respond to treatment. 1, 2 Our group has demonstrated that there is a biphasic curvilinear relationship between plasma levels of nortriptyline and behavior, using the tail suspension test, 3 an animal model employed to screen for drugs with antidepressant effects. Although noradrenergic drugs are known to induce c-Fos expression in central neurons, only one study has investigated the effects of nortriptyline on the expression of brain c-Fos. 4, 5 The magnitude of the therapeutic response observed with various doses of antidepressants may reflect differential activation of distinct brain areas for each dose used; therefore, we hypothesized that different doses of nortriptyline might induce different patterns of brain c-Fos expression in rats.
Wistar male rats received intraperitoneal injections of nortriptyline or desipramine (5, 10, 25 and 50 mg/kg), while control animals received saline solution by the same route. The animals were anesthetized with sodium-pentobarbital (40 mg/kg i.p.) and brains were removed after 2 h of drug or saline administration. For the determination of brain c-Fos expression, tissue preparation and immunohistochemical procedures were performed as described previously. 6 The experimental protocols were conducted according to the regulations established by the National Institutes of Health (USA). One-way analysis of variance, followed by the post hoc Dunnett t-test, was used to test for group effects on the counts of c-Fos-positive neurons in each anatomical structure. The presence of an inverted U-shaped, biphasic, curvilinear relationship between doses and c-Fos counts in drug-treated animals was recognized whenever the significant statistical difference between drug-treated and control animals, evident at the range of doses from 5 to 25 mg/kg, was no longer present at the higher dose of 50 mg/kg.
The present paper includes only the areas in which an inverted U-shaped pattern of c-Fos expression was observed. Figure 1 illustrates brain c-Fos expression after systemic administration of nortriptyline or desipramine at different doses, or saline (controls). The following hypothalamic areas are shown: lateral medial preoptic nucleus (MPOL), median preoptic nucleus (MnPO), paraventricular nucleus (PVN) and suprachiasmatic nucleus (SCh). The hippocampal region CA1 and the posteromedial hippocampal amygdala (AHiPM) are also shown. Both nortriptyline and desipramine significantly increased c-Fos expression in all these areas. Specifically, in animals treated with nortriptyline, the increase in c-Fos expression observed after the submaximal dose used (25 mg/kg) was not observed with the maximum dose of 50 mg/kg. Conversely, this curvilinear, inverted U-shaped response was not observed with desipramine in the same areas.
Previous studies have shown that c-Fos expression increases in certain regions of the brain in response to nortriptyline and desipramine, 4, 5 and the present study extends these findings. Our data also show that in six different areas (MPOL, MnPO, PVN, SCh, CA1, AHiPM), c-Fos activity displays a curvilinear, inverted U-shaped pattern following nortriptyline administration. Several clinical studies suggest a curvilinear, biphasic relationship between plasma levels and clinical outcome in nortriptyline-treated, depressed patients. This curvilinear relationship has also been clearly demonstrated using nortriptyline (but not desipramine) in the tail suspension test, an animal model for screening antidepressant drugs, in which a self-inhibiting effect of nortriptyline is evident when high doses are used. 3 Thus, our findings show that the observed clinical therapeutic window found for nortriptyline is mimicked in certain brain areas at molecular level, as measured by c-Fos expression.
The mechanisms explaining the inverted U-shaped dose-response effect of nortriptyline in clinical practice require further elucidation. The occurrence of a similar phenomenon regarding c-Fos expression in the group of animals receiving nortriptyline demonstrated here also needs clarification. There is some evidence that hydroxy-metabolites may be involved in the self-inhibiting effect of nortriptyline. 7 Indeed, nortriptyline-treated, depressed patients with high plasma levels of E-10-OH-nortriptyline have been shown to respond poorly or not at all to the treatment. In this situation, the self-inhibitory effect of nortriptyline may be explained by the fact that, at high doses, increased plasma levels of nortriptyline hydroxy-metabolites with lower therapeutic efficacy exert a pharmacological competition with the parent compound, reducing its effect. Additionally, some of the brain areas in which the pattern of c-Fos expression appears as an inverted U-shaped doseresponse curve are related to depression. Indeed, altered hippocampal volume detected by neuroimaging studies has been reported in humans. 8 Also, the hypothalamic areas studied here are involved in the regulation of hypothalamic-pituitary-adrenal function, a neuroendocrine axis that is closely related to the mechanisms triggering and maintaining depression. 9, 10 The data presented here suggest that the MPOL, MnPO, PVN, SCh, CA1 and AHiPM may be involved in depression and that functional image-based protocols should be used to scrutinize their function in depressed patients. Genetic and pharmacological studies in mice have demonstrated an important role of the m-opioid receptor (MOR) and cAMP responsive element-binding protein (CREB) in nicotine reward/dependence. We tested for an interaction between these two genes (OPRM1 and CREB1) in a human pharmacogenetic laboratory study.
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Preclinical studies support the importance of both CREB and MOR in nicotine reward.
1 Nicotine increases phosphorylation of CREB (P-CREB) in the ventral tegmental area, 1 while nicotine withdrawal decreases P-CREB. 2 Nicotine-induced P-CREB increase is absent in MOR À/À knockout (KO) mice and is also blocked by the MOR antagonist naloxone in wild-type mice. 1 The MOR promoter has a cAMPresponsive element that binds P-CREB, which is thought to drive expression of MOR. 1, 3 Finally, the CREB aDÀ/À KO and MOR À/À KO mice do not exhibit nicotine-conditioned place preference. 1, 4 We translated these findings to a human behavioral pharmacology investigation testing the role of MOR in the relative reinforcing value of nicotine. 5 We focused the genetic analysis on the functional OPRM1 A118G variant in exon1, for which the G allele is associated with reduced mRNA and protein levels. 6 Here, we report new data on the interacting effects of CREB1 and OPRM1 in nicotine reward. As described previously, 5 60 smokers (30 homozygous for the wildtype OPRM1 A118G A/A and 30 with at least one OPRM1 G allele) participated in a within-subject, double-blind investigation of effects of the MOR antagonist naltrexone (NTX) vs placebo on the relative reinforcing value of nicotine. We used a
